Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Posted on: Wednesday, 16 January 2008, 12:01 CST
LONDON, Jan. 16 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, today announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).
MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the subsequent three were carried out in conjunction with a NAC. The protocol was double-blinded and placebo-controlled. During the trial, no adverse effects were observed with blood analysis and pharmacokinetic data further indicating safety.
"We are entirely satisfied with these results," said Dr. Yuval Cohen, President of Morria. "They mark an important milestone in our clinical development plan, which aims at offering a potentially safer and more effective treatment option in the multi-billion dollar AR market." Morria plans to initiate a Phase II efficacy clinical study with 175 patients, who will be treated for six days prior to allergen challenge.
ABOUT ALLERGIC RHINITIS
Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.
ABOUT MORRIA BIOPHARMACEUTICALS Plc
Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals termed multi- functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known, but previously elusive anti-inflammatory drug target. At the same time, they also protect cells and tissues against inflammatory damage. Morria is determined to become a pivotal player in the anti-inflammatory drug market by developing and commercializing novel drugs for acute pulmonary and gastro-intestinal inflammatory diseases. For more information, please visit http://www.morria.com/.
This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order -- Persons in the business of disseminating information.
Contact: Meghan Feeks +1-212-827-0020 mfeeks@rlcinc.com
Morria Biopharmaceuticals Plc
CONTACT: Meghan Feeks, +1-212-827-0020, mfeeks@rlcinc.com, for MorriaBiopharmaceuticals Plc
Web site: http://www.morria.com/
Source: PRNewswire
Related Articles
- Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
- Morria Initiates Phase II Allergic Rhinitis Trial
- Collegium Reports FDA Filing for Rhinitis Drug
- Morria Reports Safety Results of Phase I Allergy Drug
- Morria Announces Safety Results of Phase I Antiallergic Drug
- Morria Initiates Phase I Study of Allergic Rhinitis Drug
- Callisto Announces Licensing of a New Class of Cancer Drugs With a Novel Mechanism of Action, Showing Potent Antitumor Activity
- General Research Equity Analyst Initiates Coverage of Callisto With Projected 6-Month Share Price Target of $2.20; German-Based Analyst Praises Callisto's Anti-Cancer and Other Drug Development Programs, Recommends a Buy Rating
- Protein Potential LLC Announces That a Structural Basis for Malaria Parasite Invasion of Red Blood Cells is Identified and Published, Raising Hopes for Improved Design of Anti-Malaria Vaccines and Drugs
- Peregrine Pharmaceuticals Submits Tarvacin(TM) Anti-Viral Investigational New Drug Application
 |
 |
User Comments (0)
RSS Feeds